Papers of the Week

Hepatitis C virus (HCV) infections are more common among US veterans receiving care through Veterans Affairs (VA) Medical Centers than among the general population. Historically, HCV therapies had lower efficacy rates in VA patients, possibly due to common comorbidities such as psychiatric disorders and substance abuse. The direct-acting antivirals ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r +DSV) ± ribavirin (RBV) are approved in the US for HCV genotype (GT) 1-infected adults with or without cirrhosis. This study prospectively evaluated safety and efficacy of OBV/PTV/r +DSV ±RBV in VA patients with HCV GT1 infection.